Patent Application
20190261670
The present invention relates to nutritional compositions for infants. In particular, the invention relates to infant formulas that are suitable for infants with cow's milk protein allergy.
Human breast milk and breast feeding are considered to be the optimal form of nutrition for healthy infants during the first months of life. However, there is a need for nutritional sources that can be used in addition to breast milk. Furthermore, not all infants can be breast fed and the needs of more vulnerable infants, such as preterm infants, cannot be achieved by their mother's milk, so there is also a need for alternatives to breast milk.
Nutritional compositions that satisfy the nutritional requirements of infants may be used as a substitute for or complement to human breast milk. Preferably, infant formulas should have an acceptable taste, and be hypoallergenic when targeted to infants who are allergic or at risk of allergy.
Infant formulas are typically formulated with cow's milk protein. For example, bovine whey protein and/or casein are often used as the protein source in infant formulas. However, some infants exhibit an allergy to cow's milk proteins, making such formulas unsuitable. Allergies to cows' milk and to infant formulas containing cow's milk protein may be due to the differences between the proteins in cows' milk and those in human milk. The principal recognised cow's milk allergens are alpha-lactalbumin (aLA), beta-lactoglobulin (bLG) and bovine serum albumin (BSA).
To reduce allergenicity, cow's milk proteins may be hydrolysed (e.g. enzymatically) either partially, or in the case of products intended for the management of Cow's Milk Protein Allergy (CMPA), extensively. However, such proteins must be highly processed to provide sufficient hydrolysis to reduce the risk of an allergic reaction. Such processing may be viewed unfavourably with an increasing tendency to provide more natural diets and a strong hydrolysis process also tends to have a negative impact on taste. In addition, the extensive processing increases the cost of the product formulas.
Alternatives to cow's milk protein may be used in nutritional compositions, for example soy and rice proteins. However, soy-based nutritional compositions are not recommended by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) for infants (0-12 months), because of the risk of a cross allergic response. Rice-based nutritional compositions require the addition of numerous free amino acids to provide the correct amino acid profile for infant formulas, due to the incomplete natural amino acid distribution in rice proteins. This increases cost and may provide the resulting formula with a less palatable taste. Furthermore, rice proteins are generally insoluble and require at least partial hydrolysis for solubilisation.
Infant formulas may be formulated entirely from free amino acids for infants with severe cases of multiple allergies. However, ESPGHAN guidelines indicate that such formulas should not be used as a first line solution in the case of cow's milk protein allergic infants. Furthermore, overprescription of amino acid based formulas adds to the cost burden on national health systems as amino acid based formulas are even more expensive than extensively hydrolysed formulas.
Accordingly, there is a significant need for nutritional compositions for infants that comprise less potential allergens, and preferably which require minimal processing, have good taste and have low cost. In particular, there is a need for infant formulas that are suitable for administration to infants with cow's milk protein allergy.
The inventors have developed a nutritional composition based on potato protein as the major protein source, which is naturally absent in the major allergens found in milk and soy. Accordingly, the nutritional composition may provide a naturally hypoallergenic infant formula that is suitable for infants with cow's milk protein allergy.
The inventors have found potato protein to have a well balanced amino acid profile, which is closer to that of human milk than rice or soy protein. Accordingly, less addition of free amino acids is required to provide a composition with the required nutritional profile, which renders the resulting product more cost effective and gives it a more palatable taste.
Moreover, as a result of their lower allergen profile, the potato protein components do not require extensive hydrolysis, which provides significant benefits in terms of cost and for the development of the infant, because the intact or slightly hydrolysed proteins facilitate improved gut maturation.
Furthermore, the need for an emulsifier may be reduced or removed, because the potato protein itself may provide any necessary emulsifier properties. In addition, use of potato protein provides for good acceptance, for example in terms of taste and texture of the nutritional composition.
Accordingly, in one aspect the invention provides an infant formula comprising protein, carbohydrate and fat, wherein the major source of protein is potato protein.
In one embodiment, the infant formula is for an infant with cow's milk protein allergy.
In a particularly preferred embodiment, the infant formula does not comprise dairy protein.
In a preferred embodiment, the major source of protein in the nutritional composition is potato protein and the remaining protein is plant protein.
The term “major source of protein is potato protein” means that the largest fraction of the total protein by weight in a composition originates from potato protein.
In one embodiment, at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%, preferably 75%, by weight of the total protein is potato protein.
In a preferred embodiment, 100% by weight of the total protein is potato protein.
In a preferred embodiment, the protein (in particular, the potato protein) is intact protein.
Preferably, the protein has not been subjected to artificial hydrolysis.
In another embodiment, the protein (in particular, the potato protein) is partially hydrolysed protein.
In another embodiment, the protein (in particular, the potato protein) is extensively hydrolysed protein.
In one embodiment, the infant formula further comprises free amino acids.
In one embodiment, the infant formula does not comprise a further emulsifier. The potato protein may provide sufficient function as an emulsifier.
In one embodiment, the infant formula is in the form of a powder or liquid. The liquid may be, for example, a concentrated liquid infant formula or a ready-to-feed formula. In one embodiment, the infant formula is in the form of a reconstituted infant formula (i.e. a liquid infant formula that has been reconstituted from the powdered form). Preferably, the infant formula is in the form of a powder.
In one embodiment, the infant formula further comprises lactose. In one embodiment, the infant formula does not comprise lactose.
In one embodiment, the infant formula further comprises probiotics. In one embodiment, the infant formula does not comprise probiotics.
In one embodiment, the infant formula further comprises nucleotides. In one embodiment, the infant formula does not comprise nucleotides.
In one embodiment, the infant formula comprises:
In another aspect, the invention provides the use of potato protein for the manufacture of an infant formula, wherein the major source of protein in the infant formula is potato protein.
The infant formula may be as disclosed herein.
In another aspect, the invention provides a method of feeding an infant comprising administering to the infant the infant formula of the invention.
In a preferred embodiment, the infant has cow's milk protein allergy.
In another aspect, the invention provides the infant formula of the invention for use in feeding an infant having cow's milk protein allergy.
In another aspect, the invention provides a method of making an infant formula comprising the step of admixing potato protein with at least one other component of the infant formula.
The infant formula may be as disclosed herein.
Comparison of essential amino acid levels between potato and rice protein, and FAO 2013 recommendations.
Comparison of essential amino acid levels between potato and rice protein, and FAO 2013 recommendations.
Comparison of histidine levels between potato and rice protein, and Institute of Medicine of the National Academies recommendations (assuming an infant formula intake of 1000 mL per day, with a minimum of 1.8 g protein per 100 kcal for infants of 6 months of age (or 12.6 g protein per day)).
Comparison of isoleucine, leucine, lysine and tryptophan levels between potato and rice protein, and Institute of Medicine of the National Academies recommendations (assuming an infant formula intake of 1000 mL per day, with a minimum of 1.8 g protein per 100 kcal for infants of 6 months of age (or 12.6 g protein per day)).
Comparison of branched-chain amino acid (BCAA) levels between potato and rice protein, and whole milk.
Comparison of mean levels of threonine and lysine between potato and rice protein, and FAO 2013 recommendations.
Comparison of mean levels of combined aromatic amino acids between potato and rice protein, and whole milk.
Various preferred features and embodiments of the present invention will now be described by way of non-limiting examples.
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, biochemistry, molecular biology, microbiology and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, Ch. 9, 13 and 16, John Wiley & Sons; Roe, B., Crabtree, J. and Kahn, A. (1996) DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons; Polak, J. M. and McGee, J. O'D. (1990) In Situ Hybridization: Principles and Practice, Oxford University Press; Gait, M. J. (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; and Lilley, D. M. and Dahlberg, J. E. (1992) Methods in Enzymology: DNA Structures Part A: Synthesis and Physical Analysis of DNA, Academic Press. Each of these general texts is herein incorporated by reference.
Infant
The subjects referred to in the present disclosure as the target of the nutritional compositions disclosed herein are human subjects.
The term “infant” refers to a child under the age of 12 months, for example a child between 0 and 6 months of age.
Allergy
The term “allergy” refers to a hypersensitivity of the immune system to a substance which is normally tolerated. The allergy may be an allergy detected by a medical doctor.
The term “food allergy” refers to an allergy with respect to a nutritional composition.
Infant formulas are typically formulated with cow's milk protein. For example, bovine whey protein and/or casein are often used as the protein source in infant formulas. However, some infants exhibit an allergy to cow's milk proteins, making such formulas unsuitable.
Allergies to cows' milk and to infant formulas containing cow's milk protein may be due to the differences between the proteins in cows' milk and those in human milk. The principal recognised cow's milk allergens are alpha-lactalbumin (aLA), beta-lactoglobulin (bLG) and bovine serum albumin (BSA).
Infant Formula
The term “infant formula” may refer to a foodstuff intended for particular nutritional use by infants during the first year of life and satisfying by itself the nutritional requirements of this category of person, as defined in European Commission Directive 2006/141/EC of 22 Dec. 2006.
Infants can be fed solely with infant formulas or the infant formula can be used as a complement of human milk.
The term “infant formula” includes hypoallergenic infant formulas. A hypoallergenic composition is a composition which is unlikely to cause allergic reactions.
The infant formula of the invention may be in the form of a powder or liquid. The liquid may be, for example, a concentrated liquid infant formula or a ready-to-feed formula. The infant formula may be in the form of a reconstituted infant formula (i.e. a liquid infant formula that has been reconstituted from the powdered form). Preferably, the infant formula is in the form of a powder.
The powder is preferably capable of being reconstituted into a liquid composition suitable for feeding an infant, for example by the addition of water. Similarly, the concentrated liquid infant formula is preferably capable of being diluted into a liquid composition suitable for feeding an infant, for example by the addition of water.
In one embodiment, the infant formula has an energy density of about 60-70 kcal per 100 mL, when formulated as instructed.
Protein
The term “protein” refers to polymers of amino acids, and includes polypeptides and peptides. The term “protein” does not encompass free amino acids, which may also be present in the infant formula of the invention.
The protein content of the infant formula of the invention is preferably in the range 1.8-3.2 g protein per 100 kcal. In a preferred embodiment, the protein content of the infant formula of the invention is in the range 1.8-2.8 g protein per 100 kcal.
The infant formula of the invention comprises potato protein as the major protein source.ln one embodiment, at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%, preferably at least about 75%, more preferably 100%, by weight of the total protein is potato protein.
The remaining protein in the infant formula of the invention may be any protein which is suitable for use in infant formula.
Preferably, the infant formula does not comprise dairy protein. Accordingly, in a preferred embodiment 100% by weight of the total protein is non-dairy protein.
In a preferred embodiment, 100% by weight of the total protein is plant protein.
Example plant proteins that may optionally be used in the infant formula of the invention, in addition to the potato protein, include, pea, rice, quinoa, oat, sunflower or coconut proteins, or combinations thereof.
Further example non-dairy proteins for use in the infant formula of the invention include algal protein or leaf protein.
In a preferred embodiment, the major source of protein in the infant formula is potato protein and the remaining protein is plant protein.
In a preferred embodiment, 100% by weight of the total protein is potato protein.
Potato protein for use in the infant formulas of the invention is readily accessible or available, for example as concentrates or isolates, for example from commercial sources.
Potato protein may be extracted from potato tuber juice, which may itself be separated from potato solids by any of a number of suitable techniques known in the art. Chromatographic techniques may be used to purify potato proteins from the tuber juice in a similar manner to the isolation of milk proteins. Once isolated, the potato protein may be concentrated and subjected to temperature treatment and/or pH adjustment. Further steps may include, for example, removal of triglycoalkaloids, spray drying and/or UV treatment.
Suitable potato protein sources include complete potato protein extract (i.e. extract not subjected to fractionation by molecular mass); and potato protein fractionated by molecular mass, for example a high molecular mass fraction (e.g. greater than 35 kDa); or a low molecular mass fraction (e.g. less than 35 kDa). In one embodiment, the potato protein source is a low molecular mass potato protein fraction of less than 35 kDa.
The protein may be, for example, intact protein or hydrolysed protein (e.g. partially hydrolysed protein). Preferably, the protein is intact protein.
Hydrolysis of protein may in general be termed “partial” or “extensive” depending on the degree to which hydrolysis is carried out. Protein hydrolysates may have an extent of hydrolysis that is characterised by NPN/TN %, which refers to the non-protein nitrogen divided by the total nitrogen ×100. The non-protein nitrogen refers to amino nitrogen that is free to react with a reagent such as trinitrobenzenesulfonic acid (TNBS). NPN/TN% may be measured as described in Adler-Nissen (Adler-Nissen, J. (1979) J. Agric. Food Chem. 27: 1256-1262).
The term “extensive hydrolysis” may refer to hydrolysis that provides protein that has a NPN/TN % greater than 95%. The term “partial hydrolysis” may refer to hydrolysis that provides protein that has a NPN/TN % in the range 70-85%.
In one embodiment, the protein has an NPN/TN% between 5-90%, 70-90% or 70-85%, preferably between 70-85%.
In one embodiment, 60-70% of the protein population has a molecular mass of less than 5000 Da.
In another embodiment, the protein has an NPN/TN% greater than 95%. These are “extensive” hydrolysates.
In one embodiment, 60-70% of the protein population has a molecular mass of less than 3000 Da. In one embodiment, at least 95% of the protein population has a molecular mass of less than 3000 Da.
Proteins for use in the infant formula of the invention may be hydrolysed by any suitable method known in the art. For example, proteins may enzymatically hydrolysed, for example using a protease.
For example, protein may be hydrolysed using alcalase (e.g. at an enzyme:substrate ratio of about 2-15% by weight and for a duration of about 1-5 hours).
Free Amino Acids
The infant formulas of the invention may further comprise free amino acids. Such free amino acids provide a protein equivalent source.
Free amino acids may be incorporated in the infant formulas of the invention to supplement the amino acids comprised in the protein. The levels of free amino acids may be chosen to provide an amino acid profile that is sufficient for infant nutrition, in particular an amino acid profile that satisfies nutritional regulations (e.g. European Commission Directive 2006/141/EC).
Example free amino acids for use in the infant formula of the invention include histidine, isoleucine, leucine, lysine, methionine, cysteine, phenylalanine, tyrosine, threonine, tryptophan, valine, alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, proline, serine, carnitine, taurine and mixtures thereof.
Carbohydrate
The carbohydrate content of the infant formula of the invention is preferably in the range 9-14 g carbohydrate per 100 kcal.
The carbohydrate may be any carbohydrate which is suitable for use in infant formula.
Example carbohydrates for use in the infant formula of the invention include lactose, saccharose, maltodextrin and starch. Mixtures of carbohydrates may be used.
In one embodiment, the carbohydrate comprises maltodextrin. In one embodiment, at least 40%, 50%, 60% or 70% by weight of the total carbohydrate is maltodextrin.
In one embodiment, the carbohydrate comprises lactose. In one embodiment, at least 40%, 50%, 60% or 70% by weight of the total carbohydrate is lactose.
In one embodiment, the carbohydrate comprises lactose and maltodextrin.
Fat
The fat content of the infant formula of the invention is preferably in the range 4.0-6.0 g lipids per 100 kcal.
The fat may be any lipid or fat which is suitable for use in infant formula.
Example fats for use in the infant formula of the invention include sunflower oil, low erucic acid rapeseed oil, safflower oil, canola oil, olive oil, coconut oil, palm kernel oil, soybean oil, fish oil, palm oleic, high oleic sunflower oil and high oleic safflower oil, and microbial fermentation oil containing long chain, polyunsaturated fatty acids.
The fat may also be in the form of fractions derived from these oils, such as palm olein, medium chain triglycerides and esters of fatty acids such as arachidonic acid, linoleic acid, palmitic acid, stearic acid, docosahexaeonic acid, linolenic acid, oleic acid, lauric acid, capric acid, caprylic acid, caproic acid, and the like.
Further example fats include structured lipids (i.e. lipids that are modified chemically or enzymatically in order to change their structure). Preferably, the structured lipids are sn2 structured lipids, for example comprising triglycerides having an elevated level of palmitic acid at the sn2 position of the triglyceride.
Oils containing high quantities of preformed arachidonic acid and/or docosahexaenoic acid, such as fish oils or microbial oils, may also be added.
Long chain polyunsaturated fatty acids, such as dihomo-y-linolenic acid, arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid, may be added. Willemsen et al. showed that the addition of such fatty acids supported epithelial barrier integrity and reduced IL-4 mediated permeability (Willemsen, L.E. et al. (2008) Eur. J. Nutr. 47: 183-91).
Structured lipids may be added or may be omitted. Medium chain triglycerides may be added or may be omitted.
Further Ingredients
The infant formula of the invention preferably also contains all vitamins and minerals understood to be essential in the daily diet in nutritionally significant amounts. Minimum requirements have been established for certain vitamins and minerals.
Example vitamins, minerals and other nutrients for use in the infant formula of the invention include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chlorine, potassium, sodium, selenium, chromium, molybdenum, taurine and L-carnitine.
Minerals are usually added in their salt form.
The infant formula of the invention may also comprise at least one probiotic. The term “probiotic” refers to microbial cell preparations or components of microbial cells with beneficial effects on the health or well-being of the host (Salminen, S. et al. (1999) Trends Food Sci. Technol. 10: 107-10).
In particular, probiotics may improve gut barrier function (Rao, R.K. (2013) Curr. Nutr. Food Sci. 9: 99-107).
Preferred probiotics are those which as a whole are safe, are L(+) lactic acid producing cultures and have acceptable shelf-life for products that are required to remain stable and effective for up to 24 months.
Examples of probiotic micro-organisms for use in the infant formula of the invention include yeasts, such as Saccharomyces, Debaromyces, Candida, Pichia and Torulopsis; and bacteria, such as the genera Bifidobacterium, Bacteroides, Clostridium, Fusobacterium, Melissococcus, Propionibacterium, Streptococcus, Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus and Lactobacillus.
Specific examples of suitable probiotic microorganisms are: Saccharomyces cereviseae, Bacillus coagulans, Bacillus licheniformis, Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Enterococcus faecium, Enterococcus faecalis, Lactobacillus acidophilus, Lactobacillus alimentarius, Lactobacillus casei subsp. casei, Lactobacillus casei Shirota, Lactobacillus curvatus, Lactobacillus delbruckii subsp. lactis, Lactobacillus farciminus, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus johnsonii, Lactobacillus rhamnosus (Lactobacillus GG), Lactobacillus sake, Lactococcus lactis, Micrococcus varians, Pediococcus acidilactici, Pediococcus pentosaceus, Pediococcus acidilactici, Pediococcus halophilus, Streptococcus faecalis, Streptococcus thermophilus, Staphylococcus carnosus and Staphylococcus xylosus.
Preferred probiotic bacterial strains include Lactobacillus rhamnosus; Lactobacillus rhamnosus LPR (CGMCC 1.3724); Bifidobacterium lactis BL818 (CNCM 1-3446) sold inter alia by the Christian Hansen company of Denmark under the trade mark BB 12; and Bifidobacterium longum BL999 (ATCC BAA-999) sold by Morinaga Milk Industry Co. Ltd. of Japan under the trade mark BB536.
The infant formula of the invention may also contain other substances which may have a beneficial effect such as human milk oligosaccharides, prebiotics, lactoferrin, fibres, nucleotides, nucleosides and the like.
Method of Manufacture
The infant formula of the invention may be prepared in any suitable manner. For example, it may be prepared by blending together the protein source, the carbohydrate source and the fat source in appropriate proportions. If used, the further emulsifiers may be included at this point. The vitamins and minerals may be added at this point but vitamins are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved in the fat source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture. Commercially available liquefiers may be used to form the liquid mixture. The liquid mixture may then be homogenised. The liquid mixture may then be thermally treated to reduce bacterial loads. This may be carried out, for example, by means of steam injection, or using an autoclave or heat exchanger, for example a plate heat exchanger. The liquid mixture may then be cooled and/or homogenised. The pH and solid content of the homogenised mixture may be adjusted at this point. The homogenised mixture may then be transferred to a suitable drying apparatus such as a spray dryer or freeze dryer and converted to powder. If a liquid infant formula is preferred, the homogenised mixture may be sterilised, then aseptically filled into a suitable container or may be first filled into a container and then retorted.
Nutritional Comparison Between Potato Protein and Rice Protein
Potato protein contains higher levels of the following essential amino acids compared to rice protein (
The concentrations of tryptophan and the sulphur-containing amino acids are similar between potato and rice proteins.
However, rice protein contains higher concentrations of histidine than potato protein.
Overall, the essential amino acid concentrations in potato protein are better than rice protein, and may require lower levels of additional amino acid fortification.
Potato protein contains more essential amino acids in compliance with the FAO 2013 recommendations compared to rice protein (Table 1).
Although the levels of histidine are lower in potato protein than rice protein, and are lower than the FAO 2013 recommendations for 0-6 month-old infants, potato protein will still deliver histidine levels that are compliant with the 214 mg/d histidine suggested by Institute of Medicine of the National Academies Adequate Intake (Al for 0-6 month-old infants (
Furthermore, although the concentrations of isoleucine, leucine, lysine and tryptophan are lower in potato compared to the FAO 2013 recommendations, these levels are similar or higher than the levels in rice. Additionally, potato protein will meet the Institute of Medicine of the National Academies AI recommendations for these amino acids, while rice protein will not meet the recommendations for isoleucine and lysine (
The concentrations for isoleucine, leucine and lysine taken from the supplier data indicate the levels of these amino acids will be compliant with WHO 2007, 2013 and EC Directive 2006/141/EC, and codex standard (CODEX STAN 72-1981), in addition to Institute of Medicine of the National Academies Al recommendations.
Branched-Chain Amino Acids (BCAA)
Branched-chain amino acids (BCAA; leucine, isoleucine and valine) have an important role in protein synthesis. Leucine is an activator of mTOR, and promotes protein synthesis and suppress protein catabolism, resulting in maintenance of muscle protein during restricted dietary intake. Children with food allergies follow dietary restrictions, therefore they are at risk of developing malnutrition, hence consumption of plant protein with high levels of BCAAs may help maintain muscle proteins.
Additionally, the best food sources of BCAAs are meat, fish, dairy products and eggs, which may not be consumed at all, or at least consumed in smaller amounts by infants and small children with food allergies.
Lysine and Threonine
Lysine and threonine are the first and second most limiting amino acids, respectively, for protein synthesis in human subjects consuming a predominantly cereal-based diet such as wheat and rice. The main roles of lysine and threonine are in protein synthesis. Unlike other plant proteins sources such as rice and wheat proteins, potato protein has higher levels of these two amino acids, with lysine levels close to the requirement set by the FAO 2013 recommendations and threonine levels exceeding it (
The best food sources of threonine and lysine are soy, dairy products, nuts, and fish, beef or chicken. These food sources may not be consumed at all, or at least consumed in smaller amounts by infants and small children with food allergies. Therefore providing a non-animal source of protein with high concentrations of these two amino acids will benefit this paediatric population.
Aromatic Amino Acids
Phenylalanine is a precursor for tyrosine, the neurotransmitters dopamine, norepinephrine, and adrenaline, and the skin pigment melanin. Potato protein exceeds the requirements set by the FAO 2013 recommendations for 0-6 month-old infants, while rice does not meet the recommended level.
The best food sources of phenylalanine are eggs, chicken, liver, beef, milk and soybeans. These food sources may not be consumed at all, or at least consumed in smaller amounts by infants and small children with food allergies. However, the combined levels of phenylalanine and tyrosine in potato protein are similar to those in milk (
Infant Formula Sensory Evaluation
Infant formulas comprising potato protein were compared to a representative rice-based infant formula (Modilac) for sensory evaluation with a panel of 12 people (Table 2).
The potato-based infant formulas were all ranked more favourably than the rice-based formula.
Infant Formula Formulation
An infant formula may be formulated according to the recipe in Table 3.
The infant formula may optionally contain lactose.
Turbiscan analysis was carried out on the samples shown in Table 4 to test the stability of the emulsions formed.
Materials and Methods 14.0 g of the relevant sample powder was dissolved in 90 mL water at 40° C. and stirred for 2 minutes on a magnetic stirrer. 20.0 mL was transferred to a measuring cuvette and the Turbiscan measurement was immediately started. Samples were measured on a regular basis during the day at room temperature and were stored at 4° C. overnight.
Results and Discussion
Lowest emulsion stability (correlating with the highest values from the Turbiscan analysis) was observed for the second sample of the complete potato protein extract (“Full range (sample 2)”), as expected. This sample is stable for a few minutes, but starts sedimenting.
The experiments with the high molecular mass fraction (no lactose) and the first sample of the complete potato protein extract (“Full range (sample 1)”) showed good performance. The high molecular mass fraction (with lactose) and the low molecular mass fraction at both pH show extremely good performance.
All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described compositions, uses and methods of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention, which are obvious to those skilled in biochemistry and biotechnology or related fields, are intended to be within the scope of the following claims.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2017/073041 | 9/13/2017 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62393781 | Sep 2016 | US |
